ArticlebioRxiv : the preprint server for biology2025
Acetaminophen attenuates pathological pain through a mechanism that requires CB1 cannabinoid receptors and the enzyme diacylglycerol lipase in mice.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Acetaminophen (APAP) is commonly used as a pain and fever reliever, but its mechanisms remain unclear. Conflicting evidence implicates the endocannabinoid system in the effects of APAP. We tested the hypothesis that the analgesic effects of APAP were dependent upon both CB1 cannabinoid receptors and diacylglycerol lipase (DAGL), an enzyme which catalyzes formation of the endocannabinoid 2-arachidonoylglycerol. We examined the impact of APAP, administered in the presence and absence of DAGL inhibitors, on mechanical hypersensitivity in mice using models of inflammatory (induced by intraplantar injection of complete Freunds adjuvant (CFA)) and post-surgical (induced by incisional injury) pain. Pharmacological specificity was assessed using global (Rimonabant, AM251) and peripherally restricted (AM6545) CB1 antagonists. APAP produced a dose-dependent attenuation of inflammation-induced mechanical hypersensitivity, but did not alter peripheral edema in the CFA-injected paw. APAP also attenuated mechanical hypersensitivity in mice with incisional injury. The DAGL inhibitors, RHC-80267 or DO34, attenuated the anti-allodynic effects of APAP in both models of pain. CB1 receptor antagonists (Rimonabant and/or AM251) suppressed the antinociceptive effect of APAP in both pain models. The peripherally-restricted CB1 antagonist AM6545 did not alter the anti-allodynic effects of APAP. We also assessed the impact of APAP on tail-flick antinociception, locomotor behavior, and body temperature. APAP produced hypothermia and hypolocomotion at the highest dose, but these effects were not blocked by RHC-80267 or AM251. APAP did not produce tail flick antinociception. Our studies demonstrate that the analgesic effects of APAP observed in mouse models of pathological pain require both DAGL and CB1 activation. Our findings support a potential mechanism of APAP-induced analgesic action involving the enzyme DAGL and CB1 receptors.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.